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1. Abstract 
 
Background: 
The value of carotid artery stenting (CAS) for the treatment of symptomatic and 
asymptomatic carotid artery stenosis is still questioned despite its tremendous increase in 
recent years. We analysed the safety and outcome of carotid artery stenting in a prospective 
CAS registry at a tertiary teaching hospital.  
 
Methods: 
Between July 2003 and January 2009, baseline characteristics, procedural and follow-up data 
including duplex sonography of the carotid artery were prospectively collected from all 
patients undergoing CAS. Primary endpoint was defined as 30-day major adverse events 
(MAE), including death, any stroke or myocardial infarction, and mid- to long-term follow-up 
outcome included ipsilateral stroke, myocardial infarction or death. Secondary endpoint was 
defined as restenosis ≥ 50 %. 
 
Results: 
173 patients underwent 187 CAS procedures, of which one third was performed for a 
symptomatic carotid artery stenosis. In 13 patients CAS was performed bilaterally as staged 
procedures. The 30-day MAE rate was 1.6 % consisting of two contralateral strokes and one 
ipsilateral stroke. Mean follow-up time was 29.3 months. Mid- to long-term MAE was 9.8% 
with 6.9% (n=12) deaths, 2.3% (n=4) myocardial infarctions and 0.6% (n=1) ipsilateral 
stroke. The restenosis rate was 5.3 % after a mean follow-up of 22 months (range 2-73) of 
which only one required a reintervention because of restenosis of  > 70% at 9 months follow-
up. 
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Conclusion: 
Carotid artery stenting at a tertiary, teaching hospital is safe and shows an excellent patency 
rate. The low adverse event rate indicates an appropriate patient selection.  
5 
2. Introduction 
 
Stroke is one of the leading causes of death following ischemic heart disease and is one of the 
most frequent reasons of permanent disability [1]. It has been estimated that significant 
stenosis of the internal carotid artery may be the predisposing condition in 5-12 % of all 
strokes [2]. Carotid endarterectomy has been shown to reduce the risk of recurrent stroke by 
50% in patients with recent cerebrovascular symptoms associated with severe carotid artery 
stenosis [3]. Endovascular treatment with balloon angioplasty and stent implantation is an 
accepted alternative to endarterectomy [4]. However, a meta-analysis found a higher risk for 
stroke or death within 30 days after endovascular intervention [5]. Therefore, endarterectomy 
has remained the treatment of choice for carotid artery stenosis [5]. Recent results from the 
CAVATAS study have shown that the restenosis rate is higher after endovascular treatment 
than after endarterectomy, however in this study 75 % of patients have only be treated with 
balloon angioplasty without stent implantation [6]. 
In contrast, the “Stenting and Angioplasty with Protection in Patients at High Risk for 
Endarterectomy” (SAPPHIRE) trial suggested that CAS may have a better outcome than CEA 
in selected, high risk patients [7]. In contrast, the SPACE trial (Stent Protected Angioplasty 
versus Carotid Endarterectomy) failed to prove the non-inferiority of CAS for the 30-day 
complication rate but showed similar results at two years follow-up [8].  
In summary, despite all results from randomized trials the optimal indication for CAS remains 
unclear. While the EVA-3S trial has been criticized for the limited interventional experience 
requested for participation in the study [9], consensus on minimal training requirements and 
performance data of newly initiated CAS programs are lacking.  
Recently we reported on the safety of starting an interdisciplinary CAS program in 100 
patients [10]. In the present analysis, we report the continuation of that program, with special 
focus on 30-day event rate and mid-term patency rate in a teaching hospital. 
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3. Patients and Methods 
 
3.1. Carotid stenting program and patient selection 
Within a 2003 initiated academic CAS program, baseline patient characteristics, procedural 
data, and outcomes were prospectively entered in a database. The outcomes of the first 100 
consecutive patients, treated between July 2003 and November 2006, were reported [10]. 
Further 73 patients were treated by CAS between November 2006 and January 2009. 
Interventionalists experience following a CAS-fellowship-training was reported in detail 
previously. In brief, in addition to full training in coronary or peripheral interventions, prior 
experience includes 100 diagnostic cerebral angiographies and 40 CAS procedures performed 
as first or second operator under supervision of an experienced interventionalist. 
Patients were considered for revascularization in the presence of a ≥ 70 % asymptomatic or a 
≥ 50 % symptomatic stenosis of the internal carotid artery.  
 
Figure 1: Selective digital subtraction 
angiography of the left carotid bifurcation with a 
severe stenosis in a 69 year old female patient.  
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Stenosis was considered symptomatic in the presence of transient ischemic attack or stroke 
affecting the corresponding territory in the preceding six months. Stenosis severity was 
assessed by colour-coded duplexsonography (CCDS) and either confirmed by CT-, MR- or 
conventional angiography. In all patients a baseline imaging of the brain with CT or MR was 
performed and analysed by an independant neurologist. The indication for revascularization 
was made by the neurologist in all cases. After complete workup including neurological 
examination the indication for CAS was made by the neurologist. All patients underwent 
neurological examination the day after the intervention by the same neurologist. ECG and 
creatinin kinase (CK), CK-MB, and troponin were obtained on admission and one day after 
the procedure. 
 
3.2. Technique 
All patients were pretreated with aspirin 100mg and clopidogrel 75mg. During the procedure 
unfractionated heparin was administered to achieve an activated clotting time of 250-300 sec. 
Four-vessel angiography, consisting of at least a selective angiography of both common 
carotid arteries and a nonselective angiography of the subclavian and vertebral arteries was 
performed using a 5F diagnostic catheter. Extracranial and intracranial digital subtraction 
angiography of each vessel was obtained. The stenting procedure was performed wih either a 
8F guiding catheter advanced over a 125 cm-long 5F diagnostic catheter with telescoping 
technique or a 6F 90cm-long sheath. 
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All procedures were performed with proximal or distal embolic protection devices (EPD) 
according to the discretion of the interventionalist and vascular conditions. To prevent 
bradycardia and hypotension, 0.5-1.0 mg of atropine was routinely administered 
intravenously prior to balloon inflation or prior to stenting if no predilatation was performed. 
After placement of the protection device predilation was usually performed with a 3.5mm to 
4.5 mm balloon catheter (Invatec) before stent deployment, followed by postdilation (5.0mm-
6.5mm). Choice of stent was at the discretion of the interventionalist (taped, open versus 
closed cell design). Before retrieval of the protection device, final biplane angiograms of the 
stented lesion as well as intracranial views were obtained. 
 
 
Figure 2: Antero-posterior fluoroscopic view 
with protection filter (white arrow) in place 
distally to the implanted stent (black arrow). 
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Figure 3: Lateral fluoroscopic 
view of balloon dilatation of the 
implanted stented in the left 
carotid bifurcation 
Figure 4: Lateral view and 
digital subtraction angiography 
following stent implantation 
(black arrow) and balloon 
dilatation. There is no residual 
stenosis in the area of stent 
implantation but mild non-flow 
limiting spasm of the distal part 
of the internal carotid artery 
(white arrows). 
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Figure 5: Antero-posterior view 
and digital subtraction 
angiography of the left 
intracranial blood flow without 
evidence for distal embolization 
following carotid artery stent 
implantation.  
Figure 6: Lateral view of 
cerebral digital subtraction 
angiogram following selective 
left internal carotid artery 
injection following carotid artery 
stenting. 
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3.3. Outcome measures 
Follow-up consisted of CCDS and clinical examination at 1 month, 6 months and 12 months, 
and yearly thereafter. The primary outcome measures were in accordance to the SAPPHIRE 
trial. [7] At 30 days, major adverse events (MAE) consisted of the composite occurrence of 
death, stroke, or myocardial infarction (MI). In addition, death, any stroke or myocardial 
infarction at follow-up was tracked. Minor stroke was defined as focal neurological deficit 
lasting more than 24 hours with ranking score ≤ 2 and NIH stroke score ≤4, while major 
stroke was diagnosed in the presence of a ranking score > 3 or NIH score ≥ 15. Any rise in 
CK-MB or troponin or new pathological Q-waves on ECG defined MI. Restenosis was 
diagnosed in the presence of a ≥ 50 % luminal narrowing as assessed by flow velocities using 
CCDS [10]. The peak systolic velocities and the end diastolic velocities of the common and 
the internal carotid arteries were recorded with CCDS. Technical success was defined by the 
coverage of the carotid lesion with a stent in the presence of a residual stenosis of less than 50 
%. Stenosis was classified as: not significant (0–49% stenosis), moderate (50–69%), severe 
(70–99%). 
 
3.4. Statistics 
Continuous variables were expressed as mean ± standard deviation. Categorical data were 
presented as actual numbers and percentages.   
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4. Results 
 
Between July 2003 and January 2009, 183 patients had an angiography with intention for 
CAS. Ten patients were excluded from the analysis for the following reasons: In seven 
patients undergoing diagnostic angiography the revascularization procedure was not 
performed because of absence of severe stenosis (n = 5) or occlusion of the carotid artery (n = 
2), respectively. In addition, three patients were referred to carotid endarterectomy because of 
severe vessel tortuosity and hence high risk for CAS. In the above mentioned ten patients the 
procedure was stopped without any neurological or cardiovascular complications. Unilateral 
carotid artery interventions were performed in in 160 patients. One reintervention was 
performed in one patient because of restenosis at 9 months. Thirteen patients underwent 
bilateral staged CAS resulting in a total of 173 patients and 187 interventions. Of these 173 
patients undergoing 187 procedures, analysis were performed per procedures for the 30-day 
major adverse event rate and per patients for the mid- to long term follow-up. 
Mean age was 68 years (range 38-87). Comorbidities were previous cardiac intervention in 
47% of the patients and in 88% other cardiovascular problems were present (i.e. congestive 
heart failure, previous myocardial infarction or previous cerebrovascular events). This is a 
relatively high prevalence of cardiovascular comorbidities compared to the SAPPHIRE trial 
with one or more high risk features in 54 % of the cases. One third of our patients presented 
with symptomatic carotid artery stenosis, 11 % had a contralateral carotid artery occlusion 
and 6% had a restenosis after CEA (Table I). 
Technical procedural success was achieved in all cases (Table II). EPD`s were used in 98% of 
the procedures, of which a proximal EPD was used in 13 patients. Only in 2% no EPD was 
used due to severe tortuosity of the internal carotid artery. The lesions were predilated in 76 
% and postdilated in 96 % of all procedures. One stent per procedure was used in 96 %. In six 
13 
patients more than one stent was necessary to cover the lesion. In one patient, an additional 
stent was necessary to cover a dissection caused by the guiding catheter.  
During the CAS procedure in 18 (10%) patients an internal carotid artery spasm occurred 
which resolved either spontaneously or after administration of intraarterial nitroglycerine 
without any neurological complications. One patient had a seizure due to a longer period of 
hypotension during the intervention that spontaneously resolved. Periinterventional 
hemoglobin drop was observed in five patients without any postinterventional relevant 
bleeding at the access site, and most probably explained by the large volume of intravenously 
given fluid and the blood loss through the catheters during the procedure. Six patients with 
access groin hematomas were treated conservatively and no other access site complications 
were observed. 
 
4.1. 30-day outcome 
Major adverse event (MAE) rate within 30 days was 1.6 %. Three patients suffered a stroke, 
two of them were contralateral. The major ipsilateral stroke was the result of an air 
embolisation during balloon dilatation caused by a balloon defect [10]. The other two 
contralateral strokes (one minor, one major) were most likely due to periinterventional 
embolisation because of guiding catheter manipulation in the aortic arch. There were no 
deaths or MI within 30 days. There were 4% (2/50) major adverse events in symptomatic and 
0.7% (1/137) in asymptomatic carotid artery stenosis..   
 
4.3. Mid-and long-term follow-up 
The mean follow-up was 29.3 months with a follow-up range from 2-72 months. During 
follow-up, 12 patients had died (6.9%), four suffered a stroke (2.3%) and four had a MI 
(2.3%). The causes of death were the following: four patients with refractory heart failure, 
three with cancer (prostate, stomach, bottom lip), one committed suicide, one suffered a 
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rupture of an aortic aneurysm, one died as a consequence of chronic heart- and kidney 
insufficiency, atrial fibrillation, and chronic obstructive pulmonary disease, and in two 
patients the cause of death was not identified (one had an intracranial bleeding six months 
before death and suffered from coronary heart disease with chronic atrial fibrillation occurring 
six months after CAS, the other with diabetes mellitus type II,  mild insufficiency of the 
mitral and aortic valve and  diastolic dysfunction with an ejection fraction of 62 % died 23 
months after CAS). 
The four minor strokes were the same as published in the previous report [10]. One was the 
result of a thrombotic stent occlusion 17 months after CAS in a patient who had been treated 
with four endarterectomies because of recurrent restenosis previously. One contralateral 
minor stroke had occurred during surgical replacement of the aortic valve two months after 
CAS. The third stroke was due to an occlusion of the contralateral retinal artery by a 
thrombus nine months after CAS in the presence of contralateral internal carotid artery 
occlusion. The fourth contralateral stroke occurred 30 months after CAS and the patient died 
37 months after CAS. 
A total of four MIs were registered during follow-up. Two MIs occurred in two patients with 
a known coronary artery disease, 20 respectively 40 months after CAS. One suffered a MI 
during aorto-coranary bypass surgery six weeks after CAS and the fourth MI was observed 40 
months post CAS in a patient with newly detected coronary heart disease manifested with an 
acute biventricular cardial decompensation with dyspnea NYHA grade II and progredient 
angina pectoris.  
The overall MAE at follow-up was 9.2 % (Table IV). The overall death or any stroke rate was 
11 %. CCDS was performed in 74 % of all cases (139/187) six months after CAS.  The 
restenosis rate was 5.3 % (8 patients and 9 vessels with a restenosis ≥ 50%, respectively, and 
one patient with a stent occlusion). Target lesion revascularization was performed in one 
patient only due to an asymptomatic restenosis detected 9 months after CAS. 
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Table I. Baseline Characteristics 
    
  n = 173 
    
   
   Mean age, years 68 
   Range age ,years 38 - 87 
   Age > 80 years, n (%) 15 (9) 
   male gender, n (%) 126 (73) 
    
Cardiovascular risk factors, n (%)   
   Diabetes mellitus 43 (25) 
   Dislipidämia 139 (80) 
   Hypertension 150 (87) 
   Current smoking 56 (32) 
    
History of cardiovascular disease, n (%) 
   Previous PCI 93 (54) 
   Previous CAGB  81 (47) 
   Previous myocardial infarction  43 (25) 
   Congestive heart failure  13 (8) 
   Previous CEA ipsilateral  12 (7) 
   Previous CEA contralateral  9 (5) 
   Previous cerebrovascular event  95 (55) 
    
SAPPHIRE high risk characteristics, n (%) 
   ≥ 1 high risk feature  77 (45) 
   ≥2 high risk features  15 (9) 
   
Carotid lesion characteristics, n (%)                                           n = 187 
   Symptomatic stenosis * 50 (27) 
   Contralateral occlusion  20 (11) 
   Contralateral stenosis ≥ 50%  63 (34) 
   Restenosis after endarterectomy                    12 (6) 
    
PCI; percutaneous coronary intervention; CABG; coronary artery bypass grafting 
CEA; carotid endarterectomy; TIA, transient ischemic attack 
SAPPHIRE; Stenting and Angioplasty with Protection in Patients at High Risk for  
Endarterectomy trial 
*TIA or CVI (cerebrovascular insult) in the preceding 6 months 
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Table II. Procedural Data 
    
  n = 187 
    
Angiographic and Doppler parameters 
   Mean angiographic degree of stenosis,% ¹                                83 
   Doppler flow velocities ²  
      Vmax (cm/sec) ICA systolic/diastolic  (SD) 342/121 (117/58) 
      Vmax ICA/Vmax CCA          (SD) 6     (2.71) 
   
Drug regimen, n (%)  
   Pretreatment with aspirin and clopidogrel ³               186 (99) 
   Atropin administration  158 (85) 
   Any periprocedural norepinephrine                         56 (30) 
      Norepidephrine boluses                                       55 (29) 
      Norepidephrine drip at end of procedure              16 (9) 
   Unfractionated heparin  187 (100) 
   
Technical characteristics, n (%)  
   Procedural success  187 (100) 
   Emboli protection device use                                  183 (98) 
      Angioguard  76 (41) 
      Spider  15 (8) 
      Filterwire  53 (28) 
      Emboshield  26 (14) 
      Ballon occlusion device 13 (7) 
   
Stents, n (%) 187 (100) 
   More than 1 stent  6 (3) 
   Type of stent  
      Precise  129 (69) 
      Acculink, Braun, Herculink, Bigsize  6 (3) 
      Vivexx  15 (8) 
      Nexstent  4 (2) 
      Cristallo  25 (13) 
      Vascuflex  8 (4) 
   
Postdilatation, n (%) 180 (96) 
  
¹ visual estimated  
² Vmax; maximum velocity; ICA; internal carotid artery; CCA; common carotid artery 
³ One patient with aspirin allergy was treated periprocedurally with additional tirofiban   and 
discharged on clopidogrel 150 mg/day for 1 month and 75 mg/day indefinitely. SD: standard 
deviation 
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Table IV. Major Adverse Events 
  
 n (%) 
   
Within 30 days 187 procedures 
   Death 0 
   Stroke  3 (1.6) 
      Major ipsilateral  1 (0.5) 
      Major nonipsilateral  1 (0.5) 
      Minor ipsilateral 0 
      Minor nonipsilateral  1 (0.5) 
   Myocardial infarction  0 
   Death, Stroke or Myocardial infarction  3 (1.6) 
  
After 30 days 173 patients 
   Death  12 (6.9) 
   Stroke  4 (2.3) 
      Major ipsilateral 0 
      Major nonipsilateral 0 
      Minor ipsilateral  1 (0.6) 
      Minor nonipsilateral  3 (1.7) 
   Myocardial infarction  4 (2.3) 
   
Overall 173 patients 
   Death, Stroke or Myocardial infarction 16 (9.2) 
   at 30 days plus death or ipsilateral 
   stroke within 31 days of follow-up  
   
Death or any Stroke  19 (11) 
Major adverse event rates were analyzed per procedure for the 30 days post procedure and per 
patients for the mid-to-long-term follow up 
   
Table III. Periprocedural Findings and Complications of the 187 
procedures 
 
  
      n (%) 
 
Internal carotid artery spasm                                                         18 (10) 
Seizure                                                                                           1 (1) 
Blood Transfusion                                                                         6 (3) 
Femoral pseudoaneurysm, arteriovenous fistulas, dessection       0 
Endovascular or surgical treatment of femoral access required    0 
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5. Discussion 
 
The analysis of 173 patients treated with CAS at a tertiary referral hospital within a specific 
carotid stenting program demonstrates the short-and long-term safety regarding relevant end 
points well according to current recommendation guidelines. 
 
All carotid stenosis, exept three lesions, could be successfully treated. In 98 % of the 
procedures emboli protection devices (EPD) has been used without any complications. The 
benefit of EPDs has not been established in randomized controlled trials, and available data 
are conflicting [11]. In our trial the 30 days-stroke-rate by using EPDs is 1.6 %, well aware of 
the causes of the three periinterventional strokes: one due to an air embolisation and two 
caused by guidining catheter embolisation in the aortic arch before EPD was implanted.  
 
The MAE rate within 30 days was 1.6 %, corresponding to three periinterventional strokes 
and is lower than the internationally guidelines that require event rates of <3 % and < 6% for 
asymptomatic and symptomatic patients [12]. The overall ipsilateral stroke rate of only 1.2 % 
and the restenosis rate of 5.3 % at follow-up demonstrate the safety of the procedure and the 
mid- to long-term durability. Reported rates of early restenosis after CAS vary widely. Newly 
published long-term results concerning restenosis rate in the CAVATS study showed a three 
time higher incidence of developping a restenosis of ≥ 50 % in endovascular than after 
endarterectomy [6]. In this trial the incidence of restenosis rate after endovascular treatment 
by balloon dilatation was significally higher than with a stent. From the 50 patients who 
recieved a stent, 23 % of them after one year and 37 % after five years, respectively, 
developped a restenosis of ≥ 50 %, which is definitively higher than in our trial. This trial also 
demonstrated, that the greatest part of the restenoses occured after one year follow-up in each 
20 
surgical group, means that our restenosis rate result by a mean ultrasound follow-up of 22 
months is well representativ.   
 
No periprocedural myocardial infarction was observed, even though cardiac heart enzyms and 
ECG were routinely controled. That confirms the fact firstly described in SAPPHIRE trial, 
namely that the one-year-MAE- rate, means death, stroke and newly also MI included, was 
significantly lower in CAS than in CEA group, largely due to the higher incidence of 
perioperative MI in the CEA group [7]. That`s an important point because it`s known that 
patients with a carotid stenosis have a higher prevalence of coronary artery disease despite the 
abscence of cardiac symptoms [14]. 
 
The overall MAE-rate (9.2 %) according to SAPPHIRE and the Death-or-any-Stroke-rate (11 
%) are mostly driven by the higher incidence of death in comparisation with the other MAE-
factors but not correlating with long-term side effects or complications of CAS. The incidence 
of death is not surprising considered the mean age of 68 years and the high incidence of 
comorbidities.  
 
In conclusion our trial suggests that CAS is a safe method for treatment with good short-and-
long-term results.  
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